Develops skin patches that deliver allergy treatments for children with food allergies, including peanut and milk allergies.
10-K for FY2025, filed Mar 26, 2026DBV Technologies is a late-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel…View ↗
Our most advanced product candidate is Viaskin® Peanut Patch, which has been evaluated as a potential therapy for children with peanut…View ↗
The Company has earlier-stage food allergy programs including Viaskin Milk and other autoimmune inflammatory diseases.View ↗
$5.6M
10-K for FY2025, filed Mar 26, 2026
$5.6M ↗
The company is developing treatments for children with food allergies and plans, if approved, to promote the peanut patch through allergists and pediatricians, with payer teams working on coverage.
10-K for FY2025, filed Mar 26, 2026
No. It lost $146.9M in FY2025.
10-Q for Q3 FY2026, filed Oct 28, 2026
−$64.5MView ↗
8-K, filed Jun 29, 2026
DBV will take additional time to incorporate the FDA feedback and anticipates submitting the BLA in the third quarter of 2026View ↗
Flat. Revenue was $5.6M in FY2025, about the same as the $5.7M of FY2021.
Competes with Aimmune Therapeutics, Stallergenes Greer, and GSK
10-K for FY2025, filed Mar 26, 2026There is one treatment for peanut allergy in children 1 to 17 years of age approved by the FDA and the European Commission: Palforzia, a…View ↗
Loading...